PRISM BioLab Co and Receptor.AI have announced a drug discovery collaboration agreement to develop an integrated, AI-navigated, physics-guided platform for the discovery of orally available small molecules targeting intracellular protein–protein interactions (PPIs), membrane proteins, and complex receptor systems.
The Collaboration unites PRISM’s PepMetics® chemistry — conformationally rigid, three-dimensional small molecules engineered to mimic α-helix and β-turn motifs — with Receptor.AI’s physics-informed, multi-objective AI navigation engine.
By integrating their technologies, the companies aim to generate innovative hit, lead and clinical candidate compounds against PPI and membrane-protein targets that have proven challenging for conventional small molecule drug discovery, with an initial focus on metabolic diseases, including obesity.
The Collaboration will initially focus on one selected receptor target for metabolic disease. Receptor.AI will carry out molecular design using the combination of PRISM’s chemical space and Receptor.AI’s design algorithms. In parallel, the companies will jointly engage pharmaceutical partners interested in utilizing the combined capabilities of both technologies.
The Collaboration aims not only to generate clinical candidates—typically the goal of joint research — but also to showcase the power of combined technologies and to acquire specialized know‑how, which will be the basis for proposals to potential partner companies, enabling the expansion of future collaborative opportunities.
PRISM and Receptor.AI share a common philosophy of ‘pursuing new approaches to drug discovery’ — creating innovative therapeutics more rapidly, rationally, and with scientific rigour. Through this Collaboration, the companies aim to create synergies by mutually adopting state‑of‑the‑art drug discovery methods.